Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open-label, Multi-center, Single Dose, Parallel Group Study to Evaluate the Pharmacokinetics and Safety of LCI699 in Subjects With Varying Degrees of Impaired Renal Function Compared to Subjects With Normal Renal Function

Trial Profile

A Phase I, Open-label, Multi-center, Single Dose, Parallel Group Study to Evaluate the Pharmacokinetics and Safety of LCI699 in Subjects With Varying Degrees of Impaired Renal Function Compared to Subjects With Normal Renal Function

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 23 Jun 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Osilodrostat (Primary)
  • Indications Cushing syndrome; Renal impairment
  • Focus Pharmacokinetics
  • Sponsors Novartis

Most Recent Events

  • 05 Oct 2016 Status changed from recruiting to completed.
  • 05 Feb 2016 Planned End Date changed from 1 Dec 2016 to 1 Feb 2017 as reported by ClinicalTrials.gov record.
  • 05 Feb 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Feb 2017 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top